Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Floats 15-Month Review Timeline For PDUFA V; Firms Mull Tradeoff On Speed Vs. Certainty

Executive Summary

Fifteen months could become the expected review time for new molecular entity and novel biologics license applications, based on a proposed new review model.

You may also be interested in...



PDUFA V: FDA Relaxes Pre-Submission Meeting Requirement

Sponsors may have negotiated a four-month reprieve for the required pre-submission meeting in the proposed new application review system expected to be implemented with PDUFA V.

FDA Wants To Lengthen Review Time For Some Prior Approval Supplements

FDA wants to lengthen the goal for action on prior-approval manufacturing supplements as part of the PDUFA V reauthorization, but industry does not appear too willing to budge.

PDUFA V: FDA Relaxes Pre-Submission Meeting Requirement

Sponsors may have negotiated a four-month reprieve for the required pre-submission meeting in the proposed new application review system expected to be implemented with PDUFA V.

Related Content

Topics

UsernamePublicRestriction

Register

PS052925

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel